ZLDPF — Zealand Pharma A/S/ADR

—
OTC · Unknown · Unknown · CIK 2068427 · Denmark
Last close
$35.93
Market Cap
$2.43B
52W High
$83.12
52W Low
$33.08
ADV30
462
Next earnings
2026-11-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 4,000,000 4,000,000 -54,000,000 -54,000,000 19,438,000,000 3,293,000,000 2,202,000,000
Jun 2026 4,491,000,000 4,491,000,000 3,859,000,000 3,917,000,000 19,762,000,000 4,038,000,000 1,762,000,000
Mar 2026 34,000,000 34,000,000 -539,000,000 -394,000,000 15,301,000,000 3,849,000,000 832,000,000
Dec 2025 68,915,000 68,915,000 -356,544,000 -379,115,000 15,948,798,000 4,576,541,000 1,118,185,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,753,067,000
Investing CF
$-1,121,506,000
Financing CF
$-510,182,000
CapEx
$-78,073,000
Dividends Paid
—
Buybacks
$-75,170,000
EPS Diluted TTM
$149.62
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$3,165,000,000
Inventory
$0
Receivables
—
ST Investments
$10,419,000,000
EBIT TTM
$2,865,830,000
Pretax Income TTM
$2,838,762,000
Interest Exp TTM
$27,068,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,643,859,968
EBITDA
$2,324,047,104
Free Cash Flow
$-2,063,679,360
Enterprise Value
$-10,827,876,352
Total Cash
$14,456,999,936
Total Debt
$411,000,000
Shares Out
67,693,163
Trailing EPS
$6.09
Book Value
$40.56
ROE
16.3%
ROA
7.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 9,214,860,000 7,113,523,000 6,455,008,000 15,948,798,000 1,118,185,000 14,830,613,000 6,531,933,000
Dec 2024 62,691,000 -1,269,071,000 -1,078,828,000 9,505,600,000 888,858,000 8,616,742,000 -930,816,000
Dec 2023 342,788,000 -577,217,000 -703,739,000 1,979,993,000 387,154,000 1,592,839,000 -425,668,000
Dec 2022 103,986,000 -816,599,000 -1,202,135,000 1,539,806,000 723,895,000 815,911,000 -942,311,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.16

Peers — same industry

TickerNameMarket CapLastDaily %
NWL NEWELL BRANDS INC. $2.44B $5.72 —
MEIUF Meitu Inc./ADR $2.43B $0.54 —
TSCFY Tisco Financial Group Public Co Limited/ADR $2.44B $30.50 —
GDV GABELLI DIVIDEND & INCOME TRUST $2.44B $28.18 —
SOHGY ALSOK Co Ltd./ADR $2.42B $9.95 —

News headlines (Yahoo Finance, 1h cache)

Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 11:10 · Yahoo
Compugen (CGEN) Reports Q3 Loss, Beats Revenue Estimates
2026-11-09 12:10 · Yahoo
Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates
2026-11-05 13:35 · Yahoo
Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates
2026-11-04 12:55 · Yahoo
Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight
2026-11-18 06:00 · Yahoo
Zealand Pharma announces EU approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
2026-11-13 14:58 · Yahoo
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:20 · Yahoo
Zealand Pharma Announces Financial Results for the First Nine Months of 2026
2026-11-12 06:00 · Yahoo
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
2026-11-09 16:00 · Yahoo
Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial w
2026-11-09 14:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.